CHAIN Biotechnology was founded in 2015, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome.

 

CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham.

 

CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling.

 

Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

 

Board

Robert Rickman

Chairman

Dr Edward Green

Founder & Chief Executive

Dr Basil Omar

Founder & Chief Commercial Officer

Dr Mike McDonald

Non-Executive Director

Peter McPartland

Non-Executive Director

Philip Chu

Non-Executive Director

Management Team

Dr Edward Green

Founder & Chief Executive

Dr Basil Omar

Founder & Chief Commercial Officer

Ben Bradley

Technology Innovation Manager

Dr Daniela Heeg

Technical Product Manager

Dana Heldt

Research Manager

Advisory Team

Dr Stephen Taylor

Manufacturing

Dr Philip Huxley

Pre-Clinical

Michael Darsley

Regulatory

Dr Edward Green

Founder & Chief Executive

Edward is a serial biotech entrepreneur, having founded Green Biologics (value >$200M) & built into a world leader for butanol fermentation. He is a microbiologist with over 25yrs experience with anaerobic bacteria, obtaining a PhD in Biochemical Engineering from the University of Manchester Institute of Science and Technology. He has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications over the past 20 years contributing to numerous scientific publications and patents. He recently founded CHAIN Biotech, a Company focused on development and commercialisation of microbial technology for delivering biotherapeutics.

Dr Edward Green

Founder & Chief Executive

Edward is a serial biotech entrepreneur, having founded Green Biologics (value >$200M) & built into a world leader for butanol fermentation. He is a microbiologist with over 25yrs experience with anaerobic bacteria, obtaining a PhD in Biochemical Engineering from the University of Manchester Institute of Science and Technology. He has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications over the past 20 years contributing to numerous scientific publications and patents. He recently founded CHAIN Biotech, a Company focused on development and commercialisation of microbial technology for delivering biotherapeutics.

Dr Basil Omar

Founder & Chief Commercial Officer

Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical roles in semiconductors, electronic displays and advanced materials. Basil held business/marketing roles at PRTM (now PwC), Grant Thornton, Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Fund. Basil is a farming and classic car enthusiast.

Dr Basil Omar

Founder & Chief Commercial Officer

Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical roles in semiconductors, electronic displays and advanced materials. Basil held business/marketing roles at PRTM (now PwC), Grant Thornton, Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Fund. Basil is a farming and classic car enthusiast.

Ben Bradley

Business Development Manager

Ben has a first class BSc in Molecular Genetics in Biotechnology from Sussex University and an MSc in Applied Biosciences and Biotechnology from Imperial College (awarded top student). Ben also spent a year at GSK working in Bioinformatics. Prior to joining CHAIN Ben gained sales and business development skills working as a recruiter for top tier investment banks. Outside of science and business, Ben has been a successful personal trainer and swimming coach and continues to compete at masters’ swimming events.

Dana Heldt

Research Manager

Dana obtained a PhD in Biochemistry from Queen Mary University of London. After few years in academia working on engineered, artificial metabolosomes in E. coli followed by a second Postdoc involving the analysis of a variety of tomato plants for health benefits, she joined the industrial sector. Dana has spent the last 3.5 years working for Biosyntha (now ZuvaSyntha) where she has gained extensive experience in molecular biology, especially in synthetic biology and metabolic engineering modifying anaerobic bacteria and providing a platform for the production of valuable chemicals.

Dr Daniela Heeg

Technical Product Manager

Daniela earned her PhD as part of the Marie Curie Network CLOSTNET at the University of Nottingham working on Clostridium difficile spores. She continued her work on Clostridium difficile as a postdoc in Nigel Minton’s Clostridia Research Group, before joining the diagnostic company Micropathology Ltd in 2014. Daniela joins CHAIN as Technical Product Manager to oversee development and global distribution of CHAIN’s modular plasmids.​ Her extensive background and expertise in Clostridium research and technology makes her a valuable addition to the CHAIN team. Outside of Clostridia, Daniela is an avid touch rugby and cycling enthusiast.

Robert Rickman

Chairman

Robert is a director of LSE listed Carclo plc and Schroder UK Midcap Investment Trust. He is a director of a datacenter components company Rockley Photonics Ltd. he was a director of telecoms components business Bookham Technology plc (listed on LSE & Nasdaq in 2000) and Oxitec, an insect genetics company, sold to Intrexon in 2015 for £100m.

Dr Stephen Taylor

Board Advisor

Steve has a PhD in Biochemistry from Warwick and has worked for ICI, AstraZeneca, Avecia, MSD and most recently Fujifilm Diosynth as Senior Vice President responsible for Commercial. His expertise is in biopharma development, manufacture and commercialisation. After 10 years in biotech R&D, Steve was a founder of Avecia Biologics and led business development to build a global biologics CDMO with operations in USA and UK and a customer base covering pharma and biotech across North America, Asia and Europe. The business is now part of the Fujifilm Group. Steve served on the BIA board 2013-2016 and has been a major voice in promoting the UK as a centre for biopharma development currently on the Medicines Manufacturing Industry Partnership steering team. Steve is now an independent consultant.

Dr Mike McDonald

Non-Executive Director

Mike is a physician with 30 years’ experience of US and EU drug development. His past appointments include Global Vice President of Clinical Development and Medical Affairs at Eli Lilly, Chief Medical Officer at Seattle Genetics Inc., and Chief Medical Officer at Oxford Biomedica.

Peter McPartland

Non-Executive Director

Peter is an experienced, independent life sciences venture capital consultant previously with Schroder Ventures (now Permira). He co-founded and was general partner of SV Life Sciences, a leading specialist venture capital firm. From 2010 to 2017 he was a non-executive director of Redx Pharma plc, an AIM-listed early stage drug discovery and development firm.

Philip Chu

Non-Executive Director

Philip is a private investor based in Hong Kong specialising in life science companies.

Dr Philip Huxley

Pre-Clinical

Philip has a PhD in Computational Chemistry from the University of Sussex. He has a vast experience in drug discovery with a successful track record in taking projects from target validation to clinical candidate identification.

Michael Darsley

Regulatory

Michael is an experienced director of in-house and outsourced Biologics and Vaccines R&D. Built and led teams outsourcing process development and clinical trial supply manufacturing for recombinant protein and live attenuated vaccines. Gained regulatory approval to move several engineered microbes into the clinic.